Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients

• Published in: Inflammatory bowel diseases Vol. 30; no. 2; pp. 167 - 182
• Main Authors: Aldars-García, Laila, Gil-Redondo, Rubén, Embade, Nieves, Riestra, Sabino, Rivero, Montserrat, Gutiérrez, Ana, Rodríguez-Lago, Iago, Fernández-Salazar, Luis, Ceballos, Daniel, Manuel Benítez, José, Aguas, Mariam, Baston-Rey, Iria, Bermejo, Fernando, José Casanova, María, Lorente, Rufo, Ber, Yolanda, Ginard, Daniel, Esteve, María, de Francisco, Ruth, José García, María, Francés, Rubén, Rodríguez Pescador, Ainhoa, Velayos, Benito, Del Río, Elena Guerra, Marín Pedrosa, Sandra, Minguez Sabater, Alejandro, Barreiro-de Acosta, Manuel, Algaba, Alicia, Verdejo Gil, Cristina, Rivas, Olga, Royo, Vanesa, Aceituno, Montserrat, Garre, Ana, Baldán-Martín, Montserrat, Ramírez, Cristina, Sanz-García, Ancor, Lozano, Juan J, Sidorova, Julia, Millet, Oscar, Bernardo, David, Gisbert, Javier P, Chaparro, María
• Format: Journal Article
• Language: English
• Published: England 01-02-2024
• Subjects: Crohn's disease; ulcerative colitis; metabolomics; inflammatory bowel disease
• ISSN: 1078-0998; 1536-4844
• DOI: 10.1093/ibd/izad154

Inflammatory bowel disease (IBD) is a prevalent chronic noncurable disease associated with profound metabolic changes. The discovery of novel molecular indicators for unraveling IBD etiopathogenesis and the diagnosis and prognosis of IBD is therefore pivotal. We sought to determine the distinctive metabolic signatures from the different IBD subgroups before treatment initiation.
Serum and urine samples from newly diagnosed treatment-naïve IBD patients and age and sex-matched healthy control (HC) individuals were investigated using proton nuclear magnetic resonance spectroscopy. Metabolic differences were identified based on univariate and multivariate statistical analyses.
A total of 137 Crohn's disease patients, 202 ulcerative colitis patients, and 338 HC individuals were included. In the IBD cohort, several distinguishable metabolites were detected within each subgroup comparison. Most of the differences revealed alterations in energy and amino acid metabolism in IBD patients, with an increased demand of the body for energy mainly through the ketone bodies. As compared with HC individuals, differences in metabolites were more marked and numerous in Crohn's disease than in ulcerative colitis patients, and in serum than in urine. In addition, clustering analysis revealed 3 distinct patient profiles with notable differences among them based on the analysis of their clinical, anthropometric, and metabolomic variables. However, relevant phenotypical differences were not found among these 3 clusters.
This study highlights the molecular alterations present within the different subgroups of newly diagnosed treatment-naïve IBD patients. The metabolomic profile of these patients may provide further understanding of pathogenic mechanisms of IBD subgroups. Serum metabotype seemed to be especially sensitive to the onset of IBD.